Organogenesis(NASDAQ) ORGO

Organogenesis Holdings Inc. makes products that help human tissue heal. These items treat painful sores and injuries for hospital patients. The company helps doctors fix muscles and bones after surgery.

Help for Wounds and Bones

• Advanced Wound Care: Dressings for chronic wounds like Diabetic Foot Ulcers (DFUs), which are sores common in diabetic patients. This segment produced $36.1 million in net product revenue during the three-month period ended June 30, 2026.
• Surgical & Sports Medicine: Solutions for bone and tissue repair, such as tendon and ligament injuries. This category accounted for $6.7 million in net product revenue during the quarter ended June 30, 2026.

Progress Toward New Products

• Completed a Biologics License Application (BLA), a request to sell a biologic product, for ReNu in April 2026.
• Received FDA acceptance for the ReNu BLA review in June 2026 with a target action date in 2027.
• Obtained a government grant in the second quarter of 2025 to build a biomanufacturing site in Rhode Island.
• Restructured operations in early 2026 to reduce the direct sales force to 148 representatives.

Why the Technology Matters

The company uses bioengineered living cell technology and amniotic membranes to promote tissue healing. These products require Premarket Approval (PMA) from the FDA, which is a rigorous regulatory clearance that limits competition.

Key Financial Facts

• Net product revenue was $42.8 million in the three-month period ended June 30, 2026, down 58% year over year.
• Advanced Wound Care sales dropped 61% year over year to $36.1 million in the three-month period ended June 30, 2026.
• The company reported a net loss of $96.3 million in the three-month period ended June 30, 2026.
• Cash and cash equivalents totaled $46.1 million as of June 30, 2026.
• Gross profit declined 74% year over year to $19.1 million in the three-month period ended June 30, 2026.

Bottom Line

Organogenesis is adapting to new Medicare reimbursement rules while restructuring its sales and manufacturing operations. The company continues to advance its product pipeline to address chronic wounds and surgical needs.